Vanguard Growth ETF (VUG)
NYSEArca - NYSEArca Delayed Price. Currency in USD
- Market Realist•11 days ago
BMY plans to focus on four core strategic areas in the immuno-oncology segment, all of which are expected to boost its growth significantly in 2016.
- Market Realist•22 days ago
Otezla is Celgene’s (CELG) first immunology drug to be approved in the US in March 2014 for treating adult patients with active psoriatic arthritis.